601089 福元医药
已收盘 02-09 15:00:00
资讯
新帖
简况
股市必读：福元医药（601089）2月6日披露最新机构调研信息
中金财经 · 02-09 08:10
股市必读：福元医药（601089）2月6日披露最新机构调研信息
【私募调研记录】彤源投资调研福元医药
证券之星 · 02-09 08:00
【私募调研记录】彤源投资调研福元医药
每周股票复盘：福元医药（601089）创新药FY101进入I期临床
证券之星 · 02-08 02:18
每周股票复盘：福元医药（601089）创新药FY101进入I期临床
福元医药：有知名机构彤源投资参与的多家机构于2月5日调研我司
证券之星 · 02-06
福元医药：有知名机构彤源投资参与的多家机构于2月5日调研我司
股市必读：福元医药（601089）2月2日收盘跌9.93%，主力净流出332.16万元
证券之星 · 02-03
股市必读：福元医药（601089）2月2日收盘跌9.93%，主力净流出332.16万元
每周股票复盘：福元医药（601089）FY101临床进展符合预期
证券之星 · 02-01
每周股票复盘：福元医药（601089）FY101临床进展符合预期
福元医药（601089）披露关于变更签字会计师的公告，1月29日股价下跌2.58%
证券之星 · 01-29
福元医药（601089）披露关于变更签字会计师的公告，1月29日股价下跌2.58%
福元医药：中金资管、淡水泉基金等多家机构于1月28日调研我司
证券之星 · 01-29
福元医药：中金资管、淡水泉基金等多家机构于1月28日调研我司
【机构调研记录】华宝基金调研福元医药
证券之星 · 01-27
【机构调研记录】华宝基金调研福元医药
【私募调研记录】盘京投资调研福元医药
证券之星 · 01-27
【私募调研记录】盘京投资调研福元医药
股市必读：福元医药（601089）1月26日披露最新机构调研信息
证券之星 · 01-27
股市必读：福元医药（601089）1月26日披露最新机构调研信息
每周股票复盘：福元医药（601089）获匹维溴铵原料药批准
证券之星 · 01-18
每周股票复盘：福元医药（601089）获匹维溴铵原料药批准
福元医药（601089）披露子公司通过GMP符合性检查，1月15日股价下跌3.9%
证券之星 · 01-15
福元医药（601089）披露子公司通过GMP符合性检查，1月15日股价下跌3.9%
福元医药最新公告：子公司浙江爱生药业通过GMP符合性检查
证券之星 · 01-15
福元医药最新公告：子公司浙江爱生药业通过GMP符合性检查
福元医药（601089）披露获得化学原料药上市申请批准通知书，1月14日股价下跌1.2%
证券之星 · 01-14
福元医药（601089）披露获得化学原料药上市申请批准通知书，1月14日股价下跌1.2%
福元医药(601089.SH)：匹维溴铵原料药上市申请获得批准
智通财经 · 01-14
福元医药(601089.SH)：匹维溴铵原料药上市申请获得批准
异动快报：福元医药（601089）1月9日14点37分触及涨停板
证券之星 · 01-09
异动快报：福元医药（601089）1月9日14点37分触及涨停板
异动快报：福元医药（601089）1月5日10点31分触及涨停板
证券之星 · 01-05
异动快报：福元医药（601089）1月5日10点31分触及涨停板
每周股票复盘：福元医药（601089）FY101临床进展符合预期
证券之星 · 2025-12-28
每周股票复盘：福元医药（601089）FY101临床进展符合预期
北京福元医药变更投资者联系电话及传真号码
中金财经 · 2025-12-27
北京福元医药变更投资者联系电话及传真号码
加载更多
公司概况
公司名称：
北京福元医药股份有限公司
所属行业：
医药制造业
上市日期：
2022-06-30
主营业务：
北京福元医药股份有限公司的主营业务是药品制剂及医疗器械的研发、生产和销售。公司的主要产品是心血管系统类、慢性肾病类、皮肤病类、消化系统类、糖尿病类、精神神经系统类、妇科类、一次性使用吸氧管。公司已入选北京医药产业跨越发展工程G20企业，荣列中国药品研发综合实力百强榜。
发行价格：
14.62
{"stockData":{"symbol":"601089","market":"SH","secType":"STK","nameCN":"福元医药","latestPrice":26.75,"timestamp":1770620400000,"preClose":26.6,"halted":0,"volume":2840100,"delay":0,"changeRate":0.0056,"floatShares":480000000,"shares":480000000,"eps":0.9648,"marketStatus":"已收盘","change":0.15,"latestTime":"02-09 15:00:00","open":26.99,"high":27.18,"low":26.61,"amount":76298900,"amplitude":0.0214,"askPrice":26.75,"askSize":32,"bidPrice":26.74,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.9648,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770687000000},"marketStatusCode":5,"adr":0,"adjPreClose":26.6,"symbolType":"stock","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":29.26,"lowLimit":23.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":480000000,"isCdr":false,"pbRate":3.48,"roa":"--","peRate":27.725954,"roe":"10.35%","epsLYR":1.04,"committee":-0.111831,"marketValue":12840000000,"turnoverRate":0.0059,"status":0,"floatMarketCap":12840000000},"requestUrl":"/m/hq/s/601089","defaultTab":"news","newsList":[{"id":"2610506382","title":"股市必读：福元医药（601089）2月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2610506382","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610506382?lang=zh_cn&edition=full","pubTime":"2026-02-09 08:10","pubTimestamp":1770595859,"startTime":"0","endTime":"0","summary":"来自机构调研要点：公司于2025年12月申报IND的FY103注射液已获临床试验申请受理。目前进展最快的研发管线正处于I期临床试验阶段。公司重视投资者回报，上市以来坚持年度现金分红，累计达6.6亿元。本次续标已完成报量，将于2月9日正式报价，公司将持续关注相关进展。根据2025年4月1日披露的2024年年报，公司药品制剂毛利率为68.36%，医疗器械毛利率为47.78%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260209/32006460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2610505474","title":"【私募调研记录】彤源投资调研福元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2610505474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610505474?lang=zh_cn&edition=full","pubTime":"2026-02-09 08:00","pubTimestamp":1770595253,"startTime":"0","endTime":"0","summary":"根据市场公开信息及2月6日披露的机构调研信息，知名私募彤源投资近期对1家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司创新药主要聚焦小核酸及小核酸递送系统研发，已搭建N-ER平台，进展最快管线处于I期临床。FY101注射液I期临床效果达预期，FY103注射液于2025年年末获临床试验申请受理。2025年2月4日完成1200万股股份回购用于股权激励，上市以来累计现金分红6.6亿元。2024年药品制剂毛利率为68.36%，医疗器械毛利率为47.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026020900001184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2609254445","title":"每周股票复盘：福元医药（601089）创新药FY101进入I期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2609254445","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609254445?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:18","pubTimestamp":1770488293,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，福元医药报收于26.6元，较上周的28.9元下跌7.96%。本周，福元医药2月2日盘中最高价报28.77元。本周关注点来自机构调研要点：公司创新药FY101注射液正在按计划进行I期临床实验。来自机构调研要点：公司自主研发新药FY103注射液已获境内临床试验申请受理。小核酸是继小分子和抗体后的第三大类药物，福元医药创新药主要聚焦小核酸及小核酸递送系统的研发。截至目前进展最快的管线在进行I期临床实验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","159992","BK1574","BK0239","601089"],"gpt_icon":0},{"id":"2609561604","title":"福元医药：有知名机构彤源投资参与的多家机构于2月5日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2609561604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609561604?lang=zh_cn&edition=full","pubTime":"2026-02-06 18:01","pubTimestamp":1770372111,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年2月6日福元医药发布公告称彤源投资张翀翯、东吴证券刘若彤于2026年2月5日调研我司。小核酸是继小分子和抗体后的第三大类药物，福元医药创新药主要聚焦小核酸及小核酸递送系统的研发。截至目前进展最快的管线在进行I期临床实验。目前，此次续标已完成报量，将于2月9日正式报价，公司会对此事项保持关注。福元医药主营业务：药品制剂及医疗器械的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600030677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2608891707","title":"股市必读：福元医药（601089）2月2日收盘跌9.93%，主力净流出332.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608891707","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608891707?lang=zh_cn&edition=full","pubTime":"2026-02-03 02:30","pubTimestamp":1770057032,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，福元医药报收于26.03元，下跌9.93%，换手率2.1%，成交量10.06万手，成交额2.73亿元。当日关注点来自交易信息汇总：福元医药2月2日收盘报26.03元，跌9.93%，主力资金当日净流出332.16万元。前10个交易日中，主力资金累计净流出5483.67万元，期间股价累计下跌5.51%。2月2日资金流向显示：主力资金净流出332.16万元，占总成交额1.22%；游资资金净流入2231.2万元，占总成交额8.18%；散户资金净流出1899.04万元，占总成交额6.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300001516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2608070826","title":"每周股票复盘：福元医药（601089）FY101临床进展符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070826","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070826?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:47","pubTimestamp":1769888829,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，福元医药报收于28.9元，较上周的27.08元上涨6.72%。本周，福元医药1月30日盘中最高价报28.98元。本周关注点来自机构调研要点：FY101 I期临床效果达到公司预期。截至目前进展最快的管线在进行I期临床实验。答：目前FY101获得的I期临床效果达到公司预期，公司会根据项目进展与信息披露要求及时披露该项目进展情况，请届时关注公司公告。公司积极拥抱国家政策，截至目前共有18个品种集采中标。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2607036209","title":"福元医药（601089）披露关于变更签字会计师的公告，1月29日股价下跌2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607036209","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607036209?lang=zh_cn&edition=full","pubTime":"2026-01-29 23:00","pubTimestamp":1769698847,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，福元医药报收于27.24元，较前一交易日下跌2.58%，最新总市值为130.75亿元。近日，北京福元医药股份有限公司发布公告称，因天健会计师事务所工作安排变动，原委派的签字注册会计师朱俊杰先生变更为简艳会女士，现由廖屹峰先生、简艳会女士担任公司2025年度财务报表及内部控制审计报告的签字注册会计师。简艳会女士自2016年起成为中国注册会计师并执业，具备专业胜任能力，近三年未因执业行为受到处罚，且符合独立性要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2607673707","title":"福元医药：中金资管、淡水泉基金等多家机构于1月28日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2607673707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607673707?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:33","pubTimestamp":1769679216,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年1月29日福元医药发布公告称中金资管谢嘉豪、淡水泉基金刘潇于2026年1月28日调研我司。截至目前进展最快的管线在进行I期临床实验。公司积极拥抱国家政策，截至目前共有18个品种集采中标。关于本次活动是否涉及应披露重大信息的说明附件清单（如有）日期否2026年1月28日福元医药主营业务：药品制剂及医疗器械的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900029449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2606722761","title":"【机构调研记录】华宝基金调研福元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2606722761","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606722761?lang=zh_cn&edition=full","pubTime":"2026-01-27 08:13","pubTimestamp":1769472798,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月26日披露的机构调研信息，华宝基金近期对1家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司创新药研发聚焦未满足的临床需求，重点布局小核酸领域，已建立N-ER自主研发平台。华宝基金成立于2003年，截至目前，资产管理规模3969.35亿元，排名28/212；资产管理规模2334.18亿元，排名25/212；管理公募基金数281只，排名25/212；旗下公募基金经理43人，排名28/212。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700007132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2606227604","title":"【私募调研记录】盘京投资调研福元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2606227604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606227604?lang=zh_cn&edition=full","pubTime":"2026-01-27 08:12","pubTimestamp":1769472765,"startTime":"0","endTime":"0","summary":"根据市场公开信息及1月26日披露的机构调研信息，知名私募盘京投资近期对1家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司创新药研发聚焦未满足的临床需求，重点布局小核酸领域，已建立N-ER自主研发平台。盘京投资立足中国证券市场，聚焦中国上市公司投资机会，同时在海外市场尤其是中概股有广泛布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026012700007096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2606240994","title":"股市必读：福元医药（601089）1月26日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2606240994","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606240994?lang=zh_cn&edition=full","pubTime":"2026-01-27 01:54","pubTimestamp":1769450053,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，福元医药报收于27.98元，上涨3.32%，换手率1.72%，成交量8.24万手，成交额2.26亿元。当日关注点来自交易信息汇总：1月26日主力与游资资金合计净流入达2875.99万元，散户资金呈显著净流出。来自机构调研要点：公司自主研发新药FY103注射液已于2025年末获临床试验申请受理，后续进展将依规披露。新药FY101正按计划开展一期临床试验，当前结果符合预期，公司将依据项目进展和信息披露要求及时公布相关信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2604256719","title":"每周股票复盘：福元医药（601089）获匹维溴铵原料药批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2604256719","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604256719?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:58","pubTimestamp":1768679888,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，福元医药报收于27.38元，较上周的30.27元下跌9.55%。本周，福元医药1月13日盘中最高价报30.8元。本周关注点公司公告汇总：福元医药获匹维溴铵原料药上市申请批准。公司公告汇总：左甲状腺素钠片2025年前三季度销售额约103,480万元。公司公告汇总北京福元医药股份有限公司收到国家药品监督管理局核准签发的匹维溴铵原料药《化学原料药上市申请批准通知书》，批准编号为2026YS00021，登记号Y20240000126，有效期至2031年1月11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2603798639","title":"福元医药（601089）披露子公司通过GMP符合性检查，1月15日股价下跌3.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603798639","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603798639?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:32","pubTimestamp":1768487535,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，福元医药报收于27.59元，较前一交易日下跌3.9%，最新总市值为132.43亿元。该股当日开盘28.41元，最高28.55元，最低27.12元，成交额达2.11亿元，换手率为1.59%。近日，北京福元医药股份有限公司发布公告称，其全资子公司浙江爱生药业有限公司收到药品GMP符合性检查告知书，其片剂（激素类）生产线通过检查，检查时间为2025年10月15日至10月17日，结论为符合《药品生产质量管理规范》要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500041086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2603080236","title":"福元医药最新公告：子公司浙江爱生药业通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2603080236","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603080236?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:32","pubTimestamp":1768469546,"startTime":"0","endTime":"0","summary":"福元医药(601089.SH)公告称，全资子公司浙江爱生药业收到药品GMP符合性检查告知书，检查结果符合《药品生产质量管理规范》要求。主要生产品种左甲状腺素钠片市场情况良好，2025年前三季度中国三大终端六大市场销售额约为10.35亿元。此次通过检查有利于公司保持稳定的生产能力，满足市场需求，但药品销售受政策和市场环境影响，具有不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500028712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2603614215","title":"福元医药（601089）披露获得化学原料药上市申请批准通知书，1月14日股价下跌1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603614215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603614215?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:22","pubTimestamp":1768400535,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，福元医药报收于28.71元，较前一交易日下跌1.2%，最新总市值为137.81亿元。该股当日开盘28.8元，最高29.7元，最低28.15元，成交额达2.33亿元，换手率为1.68%。公司近日发布公告称，北京福元医药股份有限公司收到国家药品监督管理局核准签发的匹维溴铵原料药《化学原料药上市申请批准通知书》，批准编号为2026YS00021，登记号Y20240000126，有效期至2031年1月11日。此次获批将丰富公司产品线，但后续销售受政策及市场环境影响存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2603698542","title":"福元医药(601089.SH)：匹维溴铵原料药上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2603698542","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603698542?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:39","pubTimestamp":1768376389,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的匹维溴铵原料药《化学原料药上市申请批准通知书》，本次取得匹维溴铵原料药《化学原料药上市申请批准通知书》，将进一步丰富公司产品线，促进公司持续、稳定、健康地发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)：匹维溴铵原料药上市申请获得批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2602342212","title":"异动快报：福元医药（601089）1月9日14点37分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2602342212","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602342212?lang=zh_cn&edition=full","pubTime":"2026-01-09 14:40","pubTimestamp":1767940830,"startTime":"0","endTime":"0","summary":"证券之星1月9日盘中消息，14点37分福元医药触及涨停板。其所属行业化学制药目前上涨。领涨股为前沿生物。该股为创新药，医药，减肥药概念热股，当日创新药概念上涨2.37%，医药概念上涨1.45%，减肥药概念上涨1.4%。1月8日的资金流向数据方面，主力资金净流出1294.84万元，占总成交额6.48%，游资资金净流出810.33万元，占总成交额4.06%，散户资金净流入2105.17万元，占总成交额10.54%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900018637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2601307957","title":"异动快报：福元医药（601089）1月5日10点31分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2601307957","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601307957?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:35","pubTimestamp":1767580520,"startTime":"0","endTime":"0","summary":"证券之星1月5日盘中消息，10点31分福元医药触及涨停板。其所属行业化学制药目前上涨。领涨股为前沿生物。该股为医疗器械，减肥药，创新药概念热股，当日医疗器械概念上涨3.95%，减肥药概念上涨3.08%，创新药概念上涨2.77%。12月31日的资金流向数据方面，主力资金净流出383.3万元，占总成交额6.35%，游资资金净流出368.83万元，占总成交额6.11%，散户资金净流入752.13万元，占总成交额12.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500007685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2594699242","title":"每周股票复盘：福元医药（601089）FY101临床进展符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2594699242","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594699242?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:47","pubTimestamp":1766864828,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，福元医药报收于24.29元，较上周的24.22元上涨0.29%。本周，福元医药12月25日盘中最高价报24.88元。本周关注点来自机构调研要点：FY101正按计划推进一期临床试验，结果符合公司预期。来自公司公告汇总：福元医药变更投资者联系电话为010-65020399，传真为010-65021289。漷县基地整体规划产能为100亿片，一期投产后将逐步释放产能，全部建成达产后可充分满足公司未来销售增长需求，为公司长期发展提供有力的产能保障。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2594211870","title":"北京福元医药变更投资者联系电话及传真号码","url":"https://stock-news.laohu8.com/highlight/detail?id=2594211870","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594211870?lang=zh_cn&edition=full","pubTime":"2025-12-27 09:19","pubTimestamp":1766798341,"startTime":"0","endTime":"0","summary":"中访网数据 北京福元医药股份有限公司于2025年12月27日发布公告，宣布变更投资者联系电话及传真号码。根据公告，自发布之日起，公司启用新的投资者联系电话010-65020399及传真号码010-65021289，以进一步提升投资者关系管理及服务质量。公司注册地址(北京市通州区通州工业开发区广源东街8号)、电子邮箱(ir@foyou.com.cn)及邮政编码(101113)等其他联系方式保持不变。此次变更旨在优化与投资者的沟通渠道，便于投资者更便捷地获取公司信息及进行咨询。公司证券代码为601089，证券简称为福元医药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251227/31896253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","601089"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770664014323,"stockEarnings":[{"period":"1week","weight":0.0277},{"period":"1month","weight":-0.1163},{"period":"3month","weight":0.2022},{"period":"6month","weight":-0.1215},{"period":"1year","weight":0.7793},{"period":"ytd","weight":0.1146}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京福元医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22691人(较上一季度减少3.39%)","perCapita":"21153股","listingDate":"2022-06-30","address":"北京市通州区通州工业开发区广源东街8号","registeredCapital":"48000万元","survey":" 北京福元医药股份有限公司的主营业务是药品制剂及医疗器械的研发、生产和销售。公司的主要产品是心血管系统类、慢性肾病类、皮肤病类、消化系统类、糖尿病类、精神神经系统类、妇科类、一次性使用吸氧管。公司已入选北京医药产业跨越发展工程G20企业，荣列中国药品研发综合实力百强榜。","listedPrice":14.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福元医药,601089,福元医药股票,福元医药股票老虎,福元医药股票老虎国际,福元医药行情,福元医药股票行情,福元医药股价,福元医药股市,福元医药股票价格,福元医药股票交易,福元医药股票购买,福元医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}